Welcome to our dedicated page for Zevra Therapeutics SEC filings (Ticker: ZVRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zevra Therapeutics filings document the regulatory record of a Nasdaq-listed, Delaware commercial-stage rare-disease therapeutics company. Recent Form 8-K reports furnish quarterly financial results and corporate updates, record leadership and principal financial officer changes, and disclose compensatory arrangements and inducement awards tied to executive appointments.
The filing record also includes definitive proxy materials covering board matters, executive compensation and shareholder voting items. Material-event filings describe the completed transfer of Zevra's SDX portfolio, including AZSTARYS and KP1077, under an asset purchase and settlement agreement, while Exchange Act disclosures identify the company's common stock on the Nasdaq Global Select Market.
Zevra Therapeutics reported a net income of $74.7 million for the quarter ended June 30, 2025, driven largely by a $148.3 million gain on the sale of a transferable priority review voucher (PRV). Product revenue rose to $25.9 million for the quarter and $46.3 million year-to-date, led by MIPLYFFA sales of $21.5 million in the quarter.
The balance sheet strengthened with $47.7 million in cash and approximately $170.0 million in fair-value securities, bringing total assets to $256.3 million and stockholders' equity to $117.2 million. Material charges included a $58.7 million intangible-asset impairment related to OLPRUVA and an $11.7 million inventory write-down. Long-term debt was $60.7 million. The company disclosed ongoing litigation concerning the AZSTARYS license agreement.
Zevra Therapeutics announced it issued a press release on August 12, 2025 reporting financial results and corporate updates for the quarter ended June 30, 2025. The company scheduled a conference call and audio webcast for Tuesday, August 12, 2025 at 4:30 p.m. ET to discuss those results. The press release is furnished as Exhibit 99.1 to this Form 8-K and is explicitly furnished, not filed, so it is not incorporated by reference into Zevra's other securities filings. The Form 8-K does not include financial statements or tables within the filing itself.
Zevra Therapeutics, Inc. (ZVRA) – Form 4 filing dated 06/24/2025
The filing discloses an equity transaction by insider Rahsaan W. Thompson, who serves as Chief Legal & Compliance Officer and Secretary. On 06/21/2025, Thompson acquired 66,666 shares of common stock through the settlement of previously granted restricted stock units (RSUs). The transaction is coded “M,” indicating a conversion of a derivative security rather than an open-market purchase or sale.
Table II shows the RSU award underlying the transaction. The original grant totals 133,334 RSUs. According to the vesting schedule, one-third (66,666 units) vested and converted to common stock on 06/21/2025; the remaining two tranches will vest in equal annual installments, subject to continued service. Following the settlement, Thompson directly holds 66,666 shares of common stock and retains 133,334 unvested RSUs that may convert into an equal number of shares over the next two years.
No price is listed for the RSUs because the grant is equity-settled at no cash cost to the insider. There is no indication of open-market buying or selling, no mention of a 10b5-1 trading plan check-box selection, and no other classes of securities were involved. The filing is routine and does not provide information on company operations, earnings, or strategic initiatives.